Voronoi said that it has licensed out its autoimmune disease treatment program to Brickell Biotech.

Under the accord, Voronoi will receive a down payment of $5 million and can receive up to $323.5 million depending on the development progress of the treatment candidate.

The candidate inhibits the differentiation of helper T cells, which play a key role in exacerbating inflammation, and can restore the balance of the compromised immune system by inhibiting DYRK1A kinase, responsible for intracellular signaling, and promotes the differentiation of regulatory T cells that calm inflammation.

"We are convinced that the new drug, with a new mechanism of restoring a broken immune system, can improve the lives of millions of patients suffering from inflammatory diseases," Brickell Biotech CEO Robert Brown said. "It will be an opportunity to strengthen the field of skin inflammation and enhance the company's capabilities in the overall field of inflammation."

Voronoi CEO Kim Dae-kwon also said, "We are happy to partner with Brickell Biotech, which has much experience in the field."

The company will continue to achieve results in the field of precision-targeted therapies such as epidermal growth factor receptor (EGFR) C797S and human epidermal growth factor receptor 2 positive (HER2+), Kim added.